|Table of Contents|

The study of correlation between papillary thyroid microcarcinoma lymph node metastasis and BRAFV600E mutation

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2019 04
Page:
552-556
Research Field:
Publishing date:

Info

Title:
The study of correlation between papillary thyroid microcarcinoma lymph node metastasis and BRAFV600E mutation
Author(s):
Liu Pengjie1; Tang Ming2; Deng Zhiyong1; Zhang Shiwen1; Feng Zhiping1; Chen Fukun1; Lv Juan1; Liu Chao1
1.Nuclear Medical Department，Tumor Hospital of Yunnan Province,Yunnan Kunming 650118,China;2.Pathology Department,the First People's Hospital of Yunnan Province,Yunnan Kunming 650032,China.
Keywords:
papillary thyroid microcarcinoma（PTMC）; lymphatic metastasis; BRAFV600E; mutation
PACS:
R736.1
DOI:
10.3969/j.issn.1672-4992.2019.04.003
Abstract:
Objective:To study the correlation between papillary thyroid microcarcinoma (PTMC) lymph node metastasis and BRAFV600E mutation.Methods:Retrospectively analyze the BRAFV600E mutant protein of 55 patients of PTMC with lymph node metastasis (group A) and 70 patients of PTMC without lymph node metastasis (group B) through IHC.Then the correlation between PTMC and BRAFV600E mutant was analysed.Results:The gene mutation rates of total BRAFV600E（69.1%）,right PTMC （78.3%） and bilateral PTMC (83.3%) of group A were higher than that of group B (37.1%，26.7%，42.9%)（P＜0.05）.However,the mutation rate of strongly positive （23.6%） and mutation rate of left PTMC （50.0%） were not statistically significant compared with group B (11.4%,46.2%)（P＞0.05）.In group A,the BRAFV600E mutation rates of left (72.2%),right (92.0%) and bilateral thyroid (91.7%) and strongly positive rate (30.9%) in lymph node metastasis lesion had no difference compared with primary lesion (50.0%,78.3%,83.3%,23.6%) （P＞0.05）.But,the total mutation rate of the former (85.5%) was higher than the later (69.1%) （P＜0.05）.Conclusion:BRAFV600E mutation is one of the important factors that lead to early lymph node metastasis in PTMC,and the mutation of BRAFV600E detected by various methods before or after surgery indicates a high risk of lymph node metastasis.

References:

［1］Siegel R,Ma J,Zou Z,et al.Cancer statistics 2014［J］.CA Cancer J Clin，2014,64:9-29.
[2]Lee J， Song Y，Soh EY，et al.Central lymph node metastasis is an important prognostic factor in patients with papillary thyroid micro-carcinoma［J］.J Korean Med Sci， 2014 29(1):48-52.
[3]Wang TS，Goffredo P，Sosa JA， et al.Papillary thyroid micro-carcinoma:An over-treated malignancy［J］.World J Surg， 2014，38(9):2297-2303.
[4]Yu XM，Wan Y，Sippel RS，et al.Should papillary thyroid microcarcinomas be aggressively treated？An analysis of 18 445 cases［J］.Ann Surg，2011，254(4):653-660.
[5]Alzahrani AS，Xing M.Impact of lymph node metastases identified on central neck dissection (CND) on the recurrence of papillary thyroid cancer：Potential role of BRAFV600E mutation in defining CND［J］.Endocr Relat Cancer，2013，20（1）：13-22.
[6]Cohen Y,Xing M,Mambo E,et al.BRAF mutation in papillary thyroid carcinoma［J］.J Natl Cancer Inst，2003，95（8）：625-627.
[7] Xing M,Alzahrani AS,Carson KA,et al.Association between BRAFV600E mutation and recurrence of papillary thyroid cancer［J］.J Clin Oncol,2015,33(1):42-50.
[8]Xu Liangzhong,Yang Wentao.The criteria standards of immunohistochemistry results［J］.China Oncology,1996,6(4):229-231.［许良中,杨文涛.免疫组织化学反映结果的判断标准［J］.中国癌症杂志,1996,6(4):229-231.］
[9] Li Senpeng,Zhang Xiumei,Zhang Rui.BＲAF gene mutation and tumor drug resistance［J］.Journal of Pharmaceutical Ｒesearch,2013,32(8):470-472．［李森朋,张岫美,张芮．BRAF基因突变与肿瘤耐药［J］．药学研究,2013,32(8):470-472．］
[10]Ilie MI,Lassalle S,Long-Mira E,et al.Diagnostic value of immunohistochemistry for the detection of the BRAFV600E mutation in papillary thyroid carcinoma:Comparative analysis with three DNA-based assays［J］.Thyroid,2014,24(5):858-866.
[11]Dong Liru,Yang Hu,Li Shuang,et al.BRAFV600E mutation and expression of its protein in papillary thyroid carcinoma［J］.China Oncology,2017,27(4)：251-255.［董丽儒，杨虎，李双，等.甲状腺乳头状癌BRAFV600E基因突变及相关蛋白的表达［J］.中国癌症杂志，2017,27（4）：251-255.］
[12]Miccoli P,Basolo F.BRAF mutation status in papillary thyroid carcinoma:Significance for surgical strategy［J］.Langenbecks Arch Surg,2014,399(2):225-228.
[13]Yip L,Nikiforova MN,Carty SE,et al.Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation［J］.Surgery,2009,146(6):1215-1223.
[14]So YK,Son YI,Hong SD,et al.Subclinical lymph node metastasis in papillary thyroid microcarcinoma:A study of 551 resections［J］.Surgery,2010,148(3):526-531.
[15]Howell GM,Nikiforova MN,Carty SE,et al.BRAFV600E mutation independently predicts central compartment lymph node metastasis in patients with papillary thyroid cancer［J］.Ann Surg Oncol,2013,20（1）:47-52.
[16]Lee JW,Koo BS.The prognostic implication and potential role of BRAF mutation in the decision to perform elective neck dissection for thyroid cancer［J］.Gland Surgery,2013,2(4):206-211.

Memo

Memo:
昆明市西山区科技计划项目（编号：西科字42号）
Last Update: 1900-01-01